Drugdiscovery >> Drugs >> News
3822
Views
title
A new kind of anticoagulant drug is ready to shine - drugdiscovery.com


British scientists have won early financial backing for a new kind of anticoagulant drug they believe may prevent dangerous blood clots without causing bleeding - a previously unachievable goal.
Read More >>


Tags: anticoagulant, ichorcumab - July 12, 2013
Related Articles
1406
Views
Xarelto was rejected again Xarelto was rejected again
Xarelto is Bayer's and Johnson & Johnson's oral anticoagulant. FDA has voted agains it for the second time due to ACS. The drug said to be a treatment for acute coronary syndrome. Read More >>

Tags: acute coronary syndrome, acs, anticoagulant

8340
Views
The number of Xarelto side effects is increasing The number of Xarelto side effects is increasing
Bayer’s new generation oral anticoagulant drug Xarelto faces an increasing number of side effect reports. Bayer thinks that Xarelto's benefits still outweigh its risks. Read More >>

Tags: Xarelto, Bayer, anticoagulant, side effects, risk

6504
Views
New Drug Application for Delcath's drug rejected New Drug Application for Delcath's drug rejected
The FDA has issued a complete response letter (CRL) regarding the New Drug Application (NDA) for Delcath Systems’ drug MelblezTM Kit, for the treatment of patients with unresectable ocular melanoma Read More >>

Tags: new drug application, NDA, Delcath, ocular melanoma, drug, Melblez, melphalan

8593
Views
SOLIAIR™: New Respiratory Diseases Drug Discovery! SOLIAIR™: New Respiratory Diseases Drug Discovery!
SOLIAIR™ is a food supplement which has reported beneficial impact. Patients taking SOLIAIR™ reported a decrease in seasonal infections of the respiratory tract. The SOLIAIR™ is free of side eff Read More >>

Tags: Drug Development,Drug Discovery,Medicine Development,COPD Treatment,Asthma Solution,Bronchitis Therapy,Respiratory Diseases,Lung Infections,Breathing Disorders,healthcare investment,Drug Innovation,

13816
Views
Orphan Drug Designation for Hemophilia B drug ALN-AT3 Orphan Drug Designation for Hemophilia B drug ALN-AT3
FDA has approved an Orphan Drug Designation to Alnylam Pharmaceuticals’ drug ALN-AT3 for the treatment of hemophilia B. ALN AT3 is subcutaneously administered RNAi therapeutic which targets antith Read More >>

Tags: orphan drug, ALN-AT3, hemophilia B, antithrombin, RNAi,Alnylam

8751
Views
Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV Orphan Drug Designation for HPV-associated anal cancer drug - ADXS-HPV
FDA has approved an Orphan Drug Designation to Advaxis’ next generation immunotherapy drug ADXS-HPV for the treatment of human papillomavirus (HPV)-associated anal cancer. Read More >>

Tags: Advaxis, ADXS-HPV, HPV, anal cancer, human papillomavirus, immunotherapy, drug

7071
Views
Thetanix, orphan drug for pediatric Crohn's disease Thetanix, orphan drug for pediatric Crohn's disease
The FDA has granted Orphan Drug Designation to GT Biologics for its drug Thetanix (bacteroides thetaiotaomicron) for paediatric Crohn’s disease. Read More >>

Tags: paediatric, Crohn’s disease, children, drug, orphan drug, Thetanix, GT Biologic

10728
Views
Another Sanofi MS drug approved in EU Another Sanofi MS drug approved in EU
After Aubagio, Lemtrada - another Sanofi’s drug for treatment of multiple sclerosis has been approved by the European Commission. Read More >>

Tags: multiple sclerosis, Europe, new drug, Aubagio, Lemtrada

5522
Views
Orphan drug designation for Bayer’s hypertension drug riociguat Orphan drug designation for Bayer’s hypertension drug riociguat
The FDA has granted two separate orphan drug designations for riociguat, Bayer’s investigational hypertension drug, for the treatment of pulmonary arterial hypertension and chronic thromboembolic pu Read More >>

Tags: riociguat, hypertension, drug, orphan drug designation, orphan, Bayer, pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension

7870
Views
Orphan drug designation for Delcath’s liver cancer drug Orphan drug designation for Delcath’s liver cancer drug
The FDA has granted "orphan drug" status to Delcath Systems’ melphalan hidrochloride chemotherapy for the treatment of primary liver cancer (hepatocellular carcinoma). Read More >>

Tags: melphalan, liver cancer, US, orphan drug, designation, hepatocellular carcinoma, Delcath

MOST VIEWED
HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013